Showing posts with label CANCER. Show all posts
Showing posts with label CANCER. Show all posts

Monday, August 28, 2017

HOMOEOPATHIC REMEDIES FOR PROSTATE CANCER


Prostate cancer is cancer that occurs in a man's prostate — a small walnut-shaped gland that produces the seminal fluid that nourishes and transports sperm.
Prostate cancer is one of the most common types of cancer in men. Prostate cancer usually grows slowly and initially remains confined to the prostate gland, where it may not cause serious harm. While some types of prostate cancer grow slowly and may need minimal or no treatment, other types are aggressive and can spread quickly.
Prostate cancer that is detected early — when it's still confined to the prostate gland — has a better chance of successful treatment.
Causes- It's not clear what causes prostate cancer.
Doctors know that prostate cancer begins when some cells in your prostate become abnormal. Mutations in the abnormal cells' DNA cause the cells to grow and divide more rapidly than normal cells do. The abnormal cells continue living, when other cells would die. The accumulating abnormal cells form a tumor that can grow to invade nearby tissue. Some abnormal cells can break off and spread (metastasize) to other parts of the body.
Symptoms-- Prostate cancer may cause no signs or symptoms in its early stages.
Prostate cancer that is more advanced may cause signs and symptoms such as:
·         Trouble urinating
·         Decreased force in the stream of urine
·         Blood in the semen
·         Discomfort in the pelvic area
·         Bone pain
·         Erectile dysfunction
Risk factors- Factors that can increase your risk of prostate cancer include:
Older age. Your risk of prostate cancer increases as you age.
Being black. Black men have a greater risk of prostate cancer than do men of other races. In black men, prostate cancer is also more likely to be aggressive or advanced. It's not clear why this is.
Family history of prostate or breast cancer. If men in your family have had prostate cancer, your risk may be increased. Also, if you have a family history of genes that increase the risk of breast cancer (BRCA1 or BRCA2) or a very strong family history of breast cancer, your risk of prostate cancer may be higher.
Obesity. Obese men diagnosed with prostate cancer may be more likely to have advanced disease that's more difficult to treat.
Complications- Complications of prostate cancer and its treatments include:
Cancer that spreads (metastasizes). Prostate cancer can spread to nearby organs, such as your bladder, or travel through your bloodstream or lymphatic system to your bones or other organs. Prostate cancer that spreads to the bones can cause pain and broken bones. Once prostate cancer has spread to other areas of the body, it may still respond to treatment and may be controlled, but it's unlikely to be cured.
Incontinence. Both prostate cancer and its treatment can cause urinary incontinence. Treatment for incontinence depends on the type you have, how severe it is and the likelihood it will improve over time. Treatment options may include medications, catheters and surgery.
Erectile dysfunction. Erectile dysfunction can be a result of prostate cancer or its treatment, including surgery, radiation or hormone treatments. Medications, vacuum devices that assist in achieving erection and surgery are available to treat erectile dysfunction.

Screening for Prostate cancer

Whether to test healthy men with no symptoms for prostate cancer is controversial. Medical organizations don't agree on the issue of screening and whether it has benefits.
Some medical organizations recommend men consider prostate cancer screening in their 50s, or sooner for men who have risk factors for prostate cancer. Other organizations advise against screening.
Prostate screening tests might include:)
Digital rectal exam (DRE). During a DRE, your doctor inserts a gloved, lubricated finger into your rectum to examine your prostate, which is adjacent to the rectum. If your doctor finds any abnormalities in the texture, shape or size of your gland, you may need more tests.
Prostate-specific antigen (PSA) test. A blood sample is drawn from a vein in your arm and analyzed for PSA, a substance that's naturally produced by your prostate gland. It's normal for a small amount of PSA to be in your bloodstream. However, if a higher than normal level is found, it may be an indication of prostate infection, inflammation, enlargement or cancer.
PSA testing combined with DRE helps identify prostate cancers at their earliest stages, but studies have disagreed whether these tests reduce the risk of dying of
prostate cancer. For that reason, there is debate surrounding prostate cancer screening.
Diagnosis
If an abnormality is detected on a DRE or PSA test, your doctor may recommend tests to determine whether you have prostate cancer, such as:
Ultrasound. If other tests raise concerns, your doctor may use transrectal ultrasound to further evaluate your prostate. A small probe, about the size and shape of a cigar, is inserted into your rectum. The probe uses sound waves to make a picture of your prostate gland.
Collecting a sample of prostate tissue. If initial test results suggest prostate cancer, your doctor may recommend a procedure to collect a sample of cells from your prostate (prostate biopsy). Prostate biopsy is often done using a thin needle that's inserted into the prostate to collect tissue. The tissue sample is analyzed in a lab to determine whether cancer cells are present.

HOMOEOPATHIC REMEDIES
Homoeopathy today is a rapidly growing system and is being practiced all over the world.Its strength lies in its evident effectiveness as it takes a holistic approach towards the sick individual through promotion of inner balance at mental, emotional, spiritual and physical levels. When Prostate cancer   is concerned there are many effective medicines are available in Homoeopathy, but the selection depends upon the individuality of the patient, considering the mental and physical symptoms.
SABAL SERRULATA Q—Sabal serrulata is one of the top remedies for Prostate cancer with difficulty in urinating. Prostate gland become enlarged that causes cystitis. The person feels pain during urinating. Urination becomes difficult , and there is smarting , burning in urethra. Frequent desire to urinate. Feeling as if bladder too full, starting the flow was painful as if forced through narrow meatus, causes dribbling of urine.Aching pain in abdomen that extend to abdomen. Discharge of prostatic fluid during stool or urination. Sex is painful at the time of emission. Loss of sexual power is another feature due to this complaint.

CONIUM MACULATUM 1000—Conium maculatum is considered to be another excellent remedy for Prostate cancer, and should be given in high potency. Difficulty in urination, interrupted urine, urine stops and starts several times before complete voiding. After urination the person feel cutting and burning pain.Dribbling of prostatic fluid, worse stools, emotions etc.Impotence, erection imperfect and of too short duration.

CHIMAPHILA UMBELLATA Q—Chimaphila umbellata is considered when dysuria occurs.Retention and dysuria of urine with a feeling of a ball in perineum , as if sitting on a ball. The person must strain before flow comes. Costant urging to urinate. Urine is turbid and offensive , containing ropy or bloody mucus and depositing a copious sediment. There is burning and scalding during urination and straining afterwards.

CANTHARIS  200- Cantharis is considered in Prostate cancer with constant desire to urinate. The person feels intolerable tenesmus and there is cutting pain before during and after urine. Urine burning, scalding with cutting pains and intolerable urging. Urine is passed drop by drop. Urine jelly like and shreddy.

THUJA OCCIDENTALIS 30-Thuja occidentalis is considered where the person feels as if a drop was running down urethra after urination. Urinary stream is split and small. Sensation of trickling after urination. There is burning and cutting pain while urine passes. Involuntary urination at night.

MEDORRHINUM 200-Medorrhinum is considered in Prostate cancer where  heaviness of prostate occurs which painful and enlarged with painful urination. Painful tenesmus when urinating. Urine flow very slowly.

GERANIUM MACUALTUM Q, HAMAMELIS VIRGINICA  Q, CROTALUS HORRIDUS 30- Geranium maculatum , Hamamelis  virginica , Crotalus hor. should be considered if hematuria occurs in Prostate cancer.
CARCINOSIN 30—Start treatment with this remedy.






Saturday, August 19, 2017

LUNG CANCER MAY LIE DORMANT FOR OVER 20 YEARS



Lung cancers may lie dormant for over 20 years before suddenly turning into an aggressive form of the disease, says a study.
Survival from lung cancer remains devastatingly low with many new targeted treatments making a limited impact on the disease.
“By understanding how it develops we have opened up the disease’s evolutionary rule book in the hope that we can start to predict its next steps,” said Charles Swanton, professor at Cancer Research UK’s London Research Institute.
The wide variety of faults found within lung cancers explains why targeted treatments have had limited success.
Attacking a particular genetic mistake identified by a biopsy in lung cancer will only be effective against those parts of the tumour with that fault, leaving other areas to thrive and take over, the study pointed out.
The study also highlighted the role of smoking in the development of lung cancer.
Though early genetic faults are caused by smoking, as the disease evolved these became less important with the majority of faults being caused by a new process generating mutations within the tumour controlled by a protein called APOBEC.
The research highlights the need to find better ways to detect lung cancer earlier when it’s still following just one evolutionary path.
“If we can nip the disease in the bud and treat it before it has started travelling down different evolutionary routes we could make a real difference in helping more people survive the disease,” concluded professor Nic Jones, chief scientist at Cancer Research UK.
The study appeared in the journal Science.

Wednesday, August 9, 2017

BIO ENGINEERED DECOY PROTEIN MAY STOP CANCER FROM SPREADING


A team of Stanford researchers has developed a protein therapy that disrupts the process that causes cancer cells to break away from original tumor sites, travel through the blood stream and start aggressive new growths elsewhere in the body.

This process, known as metastasis, can cause cancer to spread with deadly effect.
"The majority of patients who succumb to cancer fall prey to metastatic forms of the disease," said Jennifer Cochran, an associate professor of bioengineering who describes a new therapeutic approach in Nature Chemical Biology.
Today doctors try to slow or stop metastasis with chemotherapy, but these treatments are unfortunately not very effective and have severe side effects.
The Stanford team seeks to stop metastasis, without side effects, by preventing two proteins -- Axl and Gas6 -- from interacting to initiate the spread of cancer.
Axl proteins stand like bristles on the surface of cancer cells, poised to receive biochemical signals from Gas6 proteins.
When two Gas6 proteins link with two Axls, the signals that are generated enable cancer cells to leave the original tumor site, migrate to other parts of the body and form new cancer nodules.
To stop this process Cochran used protein engineering to create a harmless version of Axl that acts like a decoy. This decoy Axl latches on to Gas6 proteins in the blood stream and prevents them from linking with and activating the Axls present on cancer cells.
In collaboration with Professor Amato Giaccia, who heads the Radiation Biology Program in Stanford's Cancer Center, the researchers gave intravenous treatments of this bioengineered decoy protein to mice with aggressive breast and ovarian cancers.
Mice in the breast cancer treatment group had 78 percent fewer metastatic nodules than untreated mice. Mice with ovarian cancer had a 90 percent reduction in metastatic nodules when treated with the engineered decoy protein.
"This is a very promising therapy that appears to be effective and non-toxic in pre-clinical experiments," Giaccia said. "It could open up a new approach to cancer treatment."
Giaccia and Cochran are scientific advisors to Ruga Corp., a biotech startup in Palo Alto that has licensed this technology from Stanford. Further preclinical and animal tests must be done before determining whether this therapy is safe and effective in humans.
Greg Lemke, of the Molecular Neurobiology Laboratory at the Salk Institute, called this "a prime example of what bioengineering can do" to open up new therapeutic approaches to treat metastatic cancer.
"One of the remarkable things about this work is the binding affinity of the decoy protein," said Lemke, a noted authority on Axl and Gas6 who was not part of the Stanford experiments.
"The decoy attaches to Gas6 up to a hundredfold more effectively than the natural Axl," Lemke said. "It really sops up Gas6 and takes it out of action."
Directed Evolution
The Stanford approach is grounded on the fact that all biological processes are driven by the interaction of proteins, the molecules that fit together in lock-and-key fashion to perform all the tasks required for living things to function.
In nature proteins evolve over millions of years. But bioengineers have developed ways to accelerate the process of improving these tiny parts using technology called directed evolution. This particular application was the subject of the doctoral thesis of Mihalis Kariolis, a bioengineering graduate student in Cochran's lab.
Using genetic manipulation, the Stanford team created millions of slightly different DNA sequences. Each DNA sequence coded for a different variant of Axl.
The researchers then used high-throughput screening to evaluate over 10 million Axl variants. Their goal was to find the variant that bound most tightly to Gas6.
Kariolis made other tweaks to enable the bioengineered decoy to remain in the bloodstream longer and also to tighten its grip on Gas6, rendering the decoy interaction virtually irreversible.
Yu Rebecca Miao, a postdoctoral scholar in Giaccia's lab, designed the testing in animals and worked with Kariolis to administer the decoy Axl to the lab mice. They also did comparison tests to show that sopping up Gas6 resulted in far fewer secondary cancer nodules.
Irimpan Mathews, a protein crystallography expert at the SLAC National Accelerator Laboratory, joined the research effort to help the team better understand the binding mechanism between the Axl decoy and Gas6.
Protein crystallography captures the interaction of two proteins in a solid form, allowing researchers to take X-ray-like images of how the atoms in each protein bind together. These images showed molecular changes that allowed the bioengineered Axl decoy to bind Gas6 far more tightly than the natural Axl protein.
Next steps
Years of work lie ahead to determine whether this protein therapy can be approved to treat cancer in humans. Bioprocess engineers must first scale up production of the Axl decoy to generate pure material for clinical tests. Clinical researchers must then perform additional animal tests in order to win approval for and to conduct human trials. These are expensive and time-consuming steps.
But these early, hopeful results suggest that the Stanford approach could become a non-toxic way to fight metastatic cancer.
Glenn Dranoff, a professor of medicine at Harvard Medical School and a leading researcher at the Dana-Farber Cancer Institute, reviewed an advance copy of the Stanford paper but was otherwise unconnected with the research. "It is a beautiful piece of biochemistry and has some nuances that make it particularly exciting," Dranoff said, noting that tumors often have more than one way to ensure their survival and propagation.
Axl has two protein cousins, Mer and Tyro3, that can also promote metastasis. Mer and Tyro3 are also activated by Gas6.
"So one therapeutic decoy might potentially affect all three related proteins that are critical in cancer development and progression," Dranoff said.


Saturday, August 5, 2017

BACTERIAL COMMUNICATION SYSTEM COULD BE USED TO STOP CANCER CELLS



Cancer, while always dangerous, truly becomes life-threatening when cancer cells begin to spread to different areas throughout the body. Now, researchers at the University of Missouri have discovered that a molecule used as a communication system by bacteria can be manipulated to prevent cancer cells from spreading. Senthil Kumar, an assistant research professor and assistant director of the Comparative Oncology and Epigenetics Laboratory at the MU College of Veterinary Medicine, says this communication system can be used to "tell" cancer cells how to act, or even to die on command.

"During an infection, bacteria release molecules which allow them to 'talk' to each other," said Kumar, the lead author of the study. "Depending on the type of molecule released, the signal will tell other bacteria to multiply, escape the immune system or even stop spreading. We found that if we introduce the 'stop spreading' bacteria molecule to cancer cells, those cells will not only stop spreading; they will begin to die as well."
In the study published in PLOS ONE, Kumar, and co-author Jeffrey Bryan, an associate professor in the MU College of Veterinary Medicine, treated human pancreatic cancer cells grown in culture with bacterial communication molecules, known as ODDHSL. After the treatment, the pancreatic cancer cells stopped multiplying, failed to migrate and began to die.
"We used pancreatic cancer cells, because those are the most robust, aggressive and hard-to-kill cancer cells that can occur in the human body," Kumar said. "To show that this molecule can not only stop the cancer cells from spreading, but actually cause them to die, is very exciting. Because this treatment shows promise in such an aggressive cancer like pancreatic cancer, we believe it could be used on other types of cancer cells and our lab is in the process of testing this treatment in other types of cancer."
Kumar says the next step in his research is to find a more efficient way to introduce the molecules to the cancer cells before animal and human testing can take place.
"Our biggest challenge right now is to find a way to introduce these molecules in an effective way," Kumar said. "At this time, we only are able to treat cancer cells with this molecule in a laboratory setting. We are now working on a better method which will allow us to treat animals with cancer to see if this therapy is truly effective. The early-stage results of this research are promising. If additional studies, including animal studies, are successful then the next step would be translating this application into clinics."




IMMUNE CELLS IN LIVER DRIVE FATTY LIVER DISEASE LIVER CANCER


Fatty liver disease -- alongside fatty liver due to massive alcohol consumption -- is mainly caused by excessive consumption of fat and sugar combined with a lack of exercise or a sedentary life style. This is referred to as non-alcoholic fatty liver disease (NAFLD). If NAFLD becomes chronic -- e.g. through the constant uptake of high lipids and high sugar combined with lack of excercise a chronic inflammatory response is triggered in the liver tissue in addition. This can lead to non-alcoholic steatohepatitis (NASH) -- a liver disease with clear detectable pathologic alteratons of the tissue.
These liver diseases (NAFLD and NASH), along with chronic viral infections, are the most common causes of liver cancer, or hepatocellular carcinoma (HCC). In the United States, about 90 million people suffer from NAFLD. In Europe, the figure is more than 40 million, and even in threshold countries like India and China, the number of people affected is rising due to increasingly unhealthy lifestyles. More worrying, in all of the above mentioned states the numbers of NAFLD and NASH patients is constantly increasing. Consequently, the incidence of HCC resulting from NASH and NAFLD is also rising worldwide. In the United States, HCC is the fastest-growing form of cancer at the moment. No efficient causal therapy exists for HCC patients of which approximately 800,000 die every year.
T cells involved in the development of fatty liver disease, NASH and HCC
The mechanisms that cause diseases such as fatty liver disease, steatohepatitis and HCC are still not widely understood. However, immune cells, particularly CD8+ T cells and NK T cells seem to play an important role. This finding was made by a team of scientists led by Prof. Mathias Heikenwälder, Prof. Matthias Tschöp, Dr. Kerstin Stemmer, Dr. Kristian Unger, Prof. Ulrike Protzer and the working group of Dr. Hans Zischka from the Helmholtz Zentrum München together with a team headed by Prof. Percy Knolle of the Technische Universität München (TUM), Prof. Achim Weber from Zurich University Hospital and Dr. Monika Wolf, Institute of Surgical Pathology, University Hospital Zurich. The animal model which was used to examine the long-term effects of metabolic syndrome* enabled the scientists to elucidate new mechanisms that cause fatty liver disease and also show how it can develop into liver cancer.
Inflammatory events offer starting point for prevention and treatment
The scientists assume that an existing metabolic imbalance results in the activation and migration of immune cells to the liver. There, the immune cells interact with liver cells and trigger an inflammatory response that damages the liver tissue and also destabilizes the metabolic activity of the liver cells. "Initially it immune cells promote fatty liver degeneration. The inflammation, which is triggered by specific immune cells, encourages the progression of fatty liver pathology and causes NASH to develop. These processes are the basis for liver cell degeneration, which can cause HCC," explains Prof. Heikenwälder, who led the study. "Our results provide completely new insights into the development of these serious liver diseases. Building on this knowledge, we now want to develop new, preventive and therapeutic strategies to combat these diseases." The initial studies are already under way in the preclinical model.
*Metabolic syndrome: a combination of obesity / abdominal adiposity, insulin resistance, raise levels of lipids in the blood and raised blood pressure.


Wednesday, July 26, 2017

LUNG CANCER SURGERY MAY YIELD BETTER RESULTS



Patients with early stage non-small cell lung cancer (NSCLC) who are otherwise healthy fare better over time if they undergo conventional surgery versus less-invasive radiosurgery to remove their cancer, according to a Yale study. The findings are scheduled to be presented at the 56th annual conference of the American Society for Radiation Oncology in San Francisco

The study used Medicare billing records of 1,078 lung cancer patients age 67 and older from across the United States to assess shorter- and longer-term complications and outcomes related to surgery versus radiosurgery (also known as stereotactic body radiotherapy, or SBRT). The patients were treated in academic and private practice settings of all sizes.
While the findings generally support current practices of treating healthier NSCLC patients with surgery rather than radiosurgery, researchers were surprised by how much better surgical patients fared long-term, said the study's first author, James B. Yu, M.D., assistant professor of therapeutic radiology at Yale School of Medicine and a member of Yale Cancer Center.
"What was dramatic to me was the relatively high rate of complications and death among surgical patients in the first three months compared with how much better they did than radiosurgery patients after 12 months, " Yu said. "While surgery may be associated with infections and complications in the short-term, it appears that patients healthy enough to undergo surgery live longer."
Yu said researchers were unable to account for unknown factors that may have affected outcomes, such as whether patients who underwent surgery had more accurate assessment of the disease's spread than those who did not; and determining definitively that surgical patients were healthier than radiosurgery patients at the time of procedure.




NOW DOGS CAN DETECT CANCER TOO


If you think dogs only sniff out hidden drugs and decomposed bodies then think again. They also have the ability to sniff out prostate cancer. Now that’s another reason that prove why they will remain our best friends!
Dogs have three-hundred million sensory receptors as against five-milion in humans. Their extraordinary sense of smell can detect the smallest of scents known to be linked to cancer instantly.
A charity, Medical Detection Dogs, is training specialist dogs to detect human diseases. Dr Claire Guest, its founder, says, what dogs are doing is actually revisiting a way in which diagnosis has been done centuries ago.



Saturday, July 22, 2017

HOMOEOPATHIC REMEDIES FOR PANCREATIC CANCER


Pancreatic cancer begins in the tissues of your pancreas — an organ in your abdomen that lies horizontally behind the lower part of your stomach. Your pancreas secretes enzymes that aid digestion and hormones that help regulate the metabolism of sugars.
Pancreatic cancer often has a poor prognosis, even when diagnosed early. Pancreatic cancer typically spreads rapidly and is seldom detected in its early stages, which is a major reason why it's a leading cause of cancer death. Signs and symptoms may not appear until pancreatic cancer is quite advanced and complete surgical removal isn't possible
Causes --It's not clear what causes pancreatic cancer.
Pancreatic cancer occurs when cells in your pancreas develop mutations in their DNA. These mutations cause cells to grow uncontrollably and to continue living after normal cells would die. These accumulating cells can form a tumor.
Most pancreatic cancer begins in the cells that line the ducts of the pancreas. This type of cancer is called pancreatic adenocarcinoma or pancreatic exocrine cancer.
Rarely, cancer can form in the hormone-producing cells of the pancreas. This type of cancer is called islet cell cancer or pancreatic endocrine cancer.
Symptoms --Signs and symptoms of pancreatic cancer often don't occur until the disease is advanced. When signs and symptoms do appear, they may include:-Upper abdominal pain that may radiate to your back, Yellowing of your skin and the whites of your eyes (jaundice), Loss of appetite, Weight loss, Depression, Blood clot
HOMOEOPATHIC REMEDIES
CARCINOSIN 1M- Start treatment with this remedy
CALCREA ARSENIC 30- Relieves burning pain of cancer in the pancreas
CONIUM MACULATUM 200- Abdomen hard and distended. Sensitive , bruised, swollen , knife like cutting pains.
HYDRASTIS  CANADENSIS 30- Loss of appetite.  Loud rumbling with dull aching , worse moving. Gastro duodenal catarrh Cutting colicky pains , better by passing flatus
IODINE 3X- Cancer of pancreas with rapid emaciation.The patient has canine hunger and eats lot of food but still loses flesh. He is always hungry because eating relieves his discomfort  temporally. He feels worse in summer and warm room

PHOSPHORUS 200- Fatty degeneration of pancreas. Oily looking stools. Excessively bleeding  cancer of the pancreas.  

Tuesday, July 11, 2017

HOMOEOPATHIC REMEDIES FOR BREAST CANCER


Breast cancer is a malignant tumor that starts in the cells of the breast. A malignant tumor is a group of cancer cells that can grow into (invade) surrounding tissues or spread (metastasize) to distant areas of the body. The disease occurs almost entirely in women, but men can get it, too.
Experts are not definitively sure what causes breast cancer. It is hard to say why one person develops the disease while another does not. We know that some risk factors can impact on a woman's likelihood of developing breast cancer. These are:
 Getting older
The older a woman gets, the higher is her risk of developing breast cancer; age is a risk factor. Over 80% of all female breast cancers occur among women aged 50+ years
 Genetics
Women who have a close relative who has/had breast or ovarian cancer  are more likely to develop breast cancer. If two close family members develop the disease, it does not necessarily mean they shared the genes that make them more vulnerable, because breast cancer is a relatively common cancer.
The majority of breast cancers are not hereditary.
Women who carry the BRCA1 and BRCA2 genes have a considerably higher risk of developing breast and/or ovarian cancer. These genes can be inherited. TP53, another gene, is also linked to greater breast cancer risk.
 A history of breast cancer
Women who have had breast cancer, even non-invasive cancer, are more likely to develop the disease again, compared to women who have no history of the disease.
Having had certain types of breast lumps
Women who have had some types of benign (non-cancerous)breast lump   are more likely to develop cancer later on. Examples include atypical ductal hyperplasia or lobular carcinoma in situ.
 Dense breast tissue
Women with more dense breast tissue have a greater chance of developing breast cancer.
Estrogen exposure
Women who started having periods earlier or entered menopause later than usual have a higher risk of developing breast cancer. This is because their bodies have been exposed toestrogen   for longer. Estrogen exposure begins when periods start, and drops dramatically during the menopause.
Obesity
Post-menopausal obese and overweight women may have a higher risk of developing breast cancer. Experts say that there are higher levels of estrogen in obese menopausal women, which may be the cause of the higher risk.
 Height
Taller-than-average women have a slightly greater likelihood of developing breast cancer than shorter-than-average women. Experts are not sure why.
 Alcohol consumption
The more alcohol a woman regularly drinks, the higher her risk of developing breast cancer is. 
Radiation exposure
Undergoing X-rays andCT scans   may raise a woman's risk of developing breast cancer slightly.
 HRT (hormone replacement therapy)
Both forms, combined and estrogen-only HRT therapies may increase a woman's risk of developing breast cancer slightly. Combined HRT causes a higher risk.
 Certain jobs
French researchers found that women who worked at night prior to a first pregnancy had a higher risk of eventually developing breast cancer.
Canadian researchers found that certain jobs, especially those that bring the human body into contact with possible carcinogens and endocrine disruptors are linked to a higher risk of developing breast cancer   Examples include bar/gambling, automotive plastics manufacturing, metal-working, food canning and agriculture. They reported their findings in the November 2012 issue of Environmental Health.

HOMOEOPATHIC REMEDIES
CARCINOSIN 200- Start treatment with this remedy
APIS MELLIFICA 30- Cancer pain is burning and stinging. The breast is indurated.
ARSENICUM IODATUM 3X- The cancer is indurated, painful  and sensitive to touch. The glands in the axillae are swollen, hard and of the size of a walnut
ASTERIAS RUBENS 30- Ulcerative stage of the cancer. Breat is hard and  painful.The patient has red face. It acts on both the breasts but better on the left.The patient is fleshy. There is lancinating pain in the breast
BARYTA IODATUM 3X- It is useful when the cancer is hard and long standing
BELLADONNA 200-It is useful when the disease is not prolonged. Breasts feel heavy , hard, hot and red and the pain is worse from lying down
BELLIS PERENNIS Q- If the breast cancer has been caused by an injury or a blow or a bite, this is a remedy in the early stages of cancer
BROMIUM 3-Acts as a palliative in  breast cancer . Menses are clotty, too early and too profuse. Watery leucorrhea. Burning in the ovaries and uterus. Bloody milk
CALCAREA FLOUR 6X- The lump in the breast is hard and stony. The cancer may have spread to the bones. There is a stabbing pain , like the thrust of a needle
CARBO ANIMALIS 30- It is useful when the tumor is only on the nipple of the breast
CHIMAPHILA UMBELLATA  Q- Tumor is painful. Breast is very large and nipple may be secreting undue milk or blood
CONDURANGO  Q- Cancer of breasts with ulcers in the corners of mouth or cramping pain in the stomach
CONIUM MACULATUM 3X- Tumor is stony hard with burning and stinging pains. Breasts swell up at the time of menstruation
HECLA LAVA 3X- It repairs bones and tissues damaged by operation of breast
HOANG NAN Q- Removes the fetid odor. It is useful if the cancer is bleeding and revives healing process
HYDRASTIS CANADENSIS 3X- Breast cancer is accompanied by constipation and distress in the abdomen after meals. Lancinating pain in the breast.
KALI MURIATICUM 6X- A lump in the breast with a nodulated feeling accompanied with a pain now and then. There may not be any discharge of blood from the nipple which may not be retracted. Axillary glands are not affected. Bunches in the breast feel quite soft and tender
LACHESIS 200-Cancer of left breast which develops a purplish appearance. It bleeds easily and the blood is decomposed. Bleeding relives pain and suffering
PHYTOLACCA DEC Q-  Very useful for treatment of secondary tumor, metastasis , of the breast. The breast is hard and very painful to touch. It has purple hue, Axillary glands are enlarged. The menses are too copious and too frequent
SCROPHULARIA NODOSA Q- A specific remedy
SILICEA 6X-It should be given when pus has formed.There are  lumps in the breasts which suppurates and discharge thick yellow offensive pus
TARENTULA CUBENSIS 30- Cancer of breasts of very old ladies

THYROIDINUM 3X- Fibroid tumor of breast 

Saturday, July 8, 2017

NEW GENE DISCOVERED THAT STOPS SPREAD OF CANCER


Scientists at the Salk Institute have identified a gene responsible for stopping the movement of cancer from the lungs to other parts of the body, indicating a new way to fight one of the world's deadliest cancers.

By identifying the cause of this metastasis -- which often happens quickly in lung cancer and results in a bleak survival rate -- Salk scientists are able to explain why some tumors are more prone to spreading than others. The newly discovered pathway, detailed today in Molecular Cell, may also help researchers understand and treat the spread of melanoma and cervical cancers.

"Lung cancer, even when it's discovered early, is often able to metastasize almost immediately and take hold throughout the body," says Reuben J. Shaw, Salk professor of molecular and cell biology and a Howard Hughes Medical Institute early career scientist. "The reason behind why some tumors do that and others don't has not been very well understood. Now, through this work, we are beginning to understand why some subsets of lung cancer are so invasive."

Lung cancer, which also affects nonsmokers, is the leading cause of cancer-related deaths in the country (estimated to be nearly 160,000 this year). The United States spends more than $12 billion on lung cancer treatments, according to the National Cancer Institute. Nevertheless, the survival rate for lung cancer is dismal: 80 percent of patients die within five years of diagnosis largely due to the disease's aggressive tendency to spread throughout the body.

To become mobile, cancer cells override cellular machinery that typically keeps cells rooted within their respective locations. Deviously, cancer can switch on and off molecular anchors protruding from the cell membrane (called focal adhesion complexes), preparing the cell for migration. This allows cancer cells to begin the processes to traverse the body through the bloodstream and take up residence in new organs.
In addition to different cancers being able to manipulate these anchors, it was also known that about a fifth of lung cancer cases are missing an anti-cancer gene called LKB1 (also known as STK11). Cancers missing LKB1 are often aggressive, rapidly spreading through the body. However, no one knew how LKB1 and focal adhesions were connected.

Now, the Salk team has found the connection and a new target for therapy: a little-known gene called DIXDC1. The researchers discovered that DIXDC1 receives instructions from LKB1 to go to focal adhesions and change their size and number.

When DIXDC1 is "turned on," half a dozen or so focal adhesions grow large and sticky, anchoring cells to their spot. When DIXDC1 is blocked or inactivated, focal adhesions become small and numerous, resulting in hundreds of small "hands" that pull the cell forward in response to extracellular cues. That increased tendency to be mobile aids in the escape from, for example, the lungs and allows tumor cells to survive travel through the bloodstream and dock at organs throughout the body.
"The communication between LKB1 and DIXDC1 is responsible for a 'stay-put' signal in cells," says first author and Ph.D. graduate student Jonathan Goodwin. "DIXDC1, which no one knew much about, turns out to be inhibited in cancer and metastasis."

Tumors, Shaw and collaborators found in the new research, have two ways to turn off this "stay-put" signal. One is by inhibiting DIXDC1 directly. The other way is by deleting LKB1, which then never sends the signal to DIXDC1 to move to the focal adhesions to anchor the cell. Given this, the scientists wondered if reactivating DIXDC1 could halt a cancer's metastasis. The team took metastatic cells, which had low levels of DIXDC1, and overexpressed the gene. The addition of DIXDC1 did indeed blunt the ability of these cells to be metastatic in vitro and in vivo.

"It was very, very surprising that this gene would be so powerful," says Goodwin. "At the start of this study, we had no idea DIXDC1 would be involved in metastasis. There are dozens of proteins that LKB1 affects; for a single one to control so much of this phenotype was not expected."
Right now, there is no specific treatment for cancers harboring LKB1 or DIXDC1 alterations, but those with a deletion of either gene would likely see results from cancer drugs that target the focal adhesions, says Shaw.

"The good news is that this finding predicts that patients missing either gene should be sensitive to new therapies targeting focal adhesion enzymes, which are currently being tested in early-stage clinical trials," says Shaw, who is also a member of the Moores Cancer Center and an adjunct professor at the University of California, San Diego.


"By identifying this unexpected connection between DIXDC1 and LKB1 in certain tumors, we have expanded the potential patient population that may be good candidates for these therapies," adds Goodwin.